PRLD
Prelude Therapeutics Incorporated
Price as of Jul 20, 2026
PRLD earnings
Prelude Therapeutics Incorporated earnings
Reported EPS and revenue history, upcoming estimates and available earnings-call summaries.
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-0.27 | $-0.13 | +51.9% | $5M | +0.0% |
| Mar 10, 2026 | $-0.03 | $-0.20 | -566.7% | $6M | -72.5% |
| Nov 12, 2025 | $-0.35 | $-0.26 | +25.7% | $7M | -68.3% |
| Aug 14, 2025 | $-0.45 | $-0.41 | +8.9% | — | — |
| Mar 10, 2025 | $-0.49 | $-0.38 | +22.4% | $4M | — |
| Feb 15, 2024 | $-0.50 | $-0.47 | +6.0% | $3M | — |
| Nov 1, 2023 | $-0.58 | $-0.45 | +22.4% | — | — |
| Aug 3, 2023 | $-0.65 | $-0.54 | +16.9% | — | — |
| Mar 15, 2023 | $-0.63 | $-0.60 | +4.8% | — | — |
| Nov 14, 2022 | $-0.63 | $-0.63 | +0.0% | — | — |
| Mar 16, 2022 | $-0.69 | $-0.71 | -2.9% | — | — |
| Nov 12, 2021 | $-0.62 | $-0.66 | -6.5% | — | — |
Earnings call summary
Q4 FY2025 · March 10, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Discussed aspects such as the clinical development plan for molecule 396 including a parallel design in myelofibrosis and polycythemia vera with input from key opinion leaders, the rationale behind choosing a degrader approach for CAT6 including selectivity and efficacy advantages, and work on the mutant Cal-R degrader with differentiation points like potency and potential for subcutaneous administration.
Guidance
Cash position was $106 million in cash, which takes the company into the second quarter of 2027, and this does not account for the potential $100 million option payment from Insight.
Segment performance
Not explicitly mentioned in detail
Risks & headwinds
Not discussed in detail
Analyst Q&A
Q: Can you differentiate your molecule from other competitors and why Insight would partner with you?
A: Discussed selectivity profile, learnings from clinic/preclinical stages, and parallel clinical development plan.
Q: Talk about the clinical development plan for molecule 396?
A: Parallel design in myelofibrosis and polycythemia vera, enrolling the right patients and getting FDA approval for the parallel approach.
Q: Talk about the CAT6 degrader?
A: Differentiated by degrader approach for better selectivity and efficacy, plan to file IND by mid - year.
Q: What is the cash position?
A: $106 million in cash, lasting into the second quarter of 2027
Earnings history is derived from company filings and calendar data. Call summaries are grouped by reporting period. Latest covered event: 2026-08-13.